Breast cancer

  1. A phase III, randomized, double-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolizumab plus chemotherapy for patients with early relapsing recurrent (inoperable locally advanced or metastatic) triple-negative breast cancer
    This study evaluates the effectiveness and safety of combination therapy with atezolizumab and cytostatic therapy when compared to the combination of placebo and cytostatic therapy in test subjects with recurrent triple-negative breast cancer that is unsuited for surgery.
    Primary reseacher: Meri Utriainen

  2. A Phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer, who have received two prior Anti-HER2 therapies and require systemic treatment
    The purpose of the study is to compare two therapies: margetuximab combined with cytostatic therapy, and trastuzumab combined with cytostatic therapy in patients with metastatic HER2-positive breast cancer who have received anti-HER2 treatment and require systemic therapy.
    Primary researcher: Johanna Mattson

  3. A randomized phase III study comparing trastuzumab, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy  to the current standard regimen as the treatments of early HER2-positive breast cancer
    The purpose of the study is to compare the effectiveness and safety of two cytostatic regimens as adjuvant therapies for HER2-positive breast cancer. The purpose is to examine if short-term therapy containing trastuzumab, pertuzumab and docetaxel is better, equally good, or worse than traditional therapy in terms of effectiveness and side effects. The traditional therapy contains trastuzumab and docetaxel.
    Primary researcher: Johanna Mattson

  4. COMPLEMEENT-1: An open label, multicenter, phase IIIb study to assess the safety anf efficacy of ribociclib (LEE001) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptorpositive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
    The purpose of this study is to evaluate the safety and efficacy of ribociclib (LEE001) when used in combination with letrozole to treat hormone receptor positive (HR+) and HER2-negative (HER2-) advanced breast cancer in men and pre/postmenopausal women who have not received hormonal therapy for advanced breast cancer previously.
    Primary researcher: Meri Utriainen
 

 Contact Information

 
haluantutkimuspotilaaksi@hus.fi
tel. +358 50 427 0680